【甘李药业：GZC8072片获2型糖尿病临床试验批准】甘李药业公告，公司全资子公司甘李药业山东有限公司近日收到国家药品监督管理局下发的GZC8072片新适应症《药物临床试验批准通知书》，同意开展2型糖尿病适应症临床试验。该产品下一阶段将按国家药品注册相关规定开展临床试验。

蒙特利尔银行：将雪佛龙(CVX.N)目标价从210美元上调至235美元。

Macklem said inflation remains too high in Canada, concentrated in gasoline and energy prices. He identified developments in the Middle East — and how long and how far oil prices stay elevated — as the main upside risk and said the BOC will closely monitor inflation data and act accordingly. The central bank’s tolerance for high inflation is limited; if inflation is judged persistent, multiple rate hikes may be required, though rate increases are not the only response and the BOC is prepared to adjust policy as needed. He said the Canadian economy is holding up amid a new phase of trade tensions, but recent U.S. tariff measures will weigh on Q4 growth. Macklem also noted spillovers from higher global bond yields into Canada and said those effects will be factored into policy decisions; if policy fails to meet its objectives, markets will reprice.